Business News

InIn the 2026 College Entrance Examination Chemistry (Henan Paper)

A major organic synthesis problem has attracted widespread attention.

Title mentioned:“Compound H is a surgical medication developed independently in China. One of its synthesis routes is as follows…”

(The image is from [End]Public information）

Industry professionals keenly noticed

in the title“Compound H”

It is a original intravenous anesthetic in China——The racemic structure of cyclobutanol

In real clinical applications

Cyclobipirone is produced using a more advanced chiral synthesis process

It uses pharmacological activityBetterthe“R-configuration single chiral isomer”

From the design scenarios in the college entrance examination questions

Innovative drugs that ultimately benefit patients

Behind this is a path of innovative breakthroughs filled with obstacles.

The emergence of cyclopelline was not accidental

Looking back at its development process, it was a long and difficult struggle to break through.

The Haisco technology R&D team has gone through the screening of tens of thousands of innovative compounds.More than 200 animal studies

FinalskilfullyA cyclopropyl group was introduced, creating a new chiral center

This one that breaks the curse“Chirality” structure

Change the underlying chemical structure to make it matchThe binding affinity of GABA receptors has increased significantly

Compared to traditional reference drugs, the effectiveness is improved by approximately5 times

The dose can be reduced to the original level while achieving the same anesthetic effect.1/5, achieving a significant increase in efficacy

Successfully overcame previous drug derivativesThe clinical challenge of “the higher the dose and the higher the potency, the stronger the side effects”

Significantly improved security

As the only product of this type reviewed in over thirty years“me-better” innovative drugs

It is the first independently developed product in China with global independent intellectual property rights.Class 1 intravenous anesthetic (launched in 2020)

Continuously receivedSupport for Major Science and Technology Projects on “Major New Drug Development”

Included in the 14-21 educational planning textbooks and incorporated intoMore than 20 authoritative guidelines agree on common principles

Entered into the national basic medical insurance list in 2022

In 2025, approval was given to expand to the children/teenage population.

Currently, there areMore than 3,300 medical institutions use it, benefiting over 40 million people

Not only rooted in the domestic market, but also leveraging head-to-head advantages to reach overseas markets.

After being approved by the FDA for clinical trials in 2021

Exempted from US duties directly due to excellent dataPhase II clinical trial, entering critical Phase III

All clinical studies will be completed in 2024

Achieved advantageous results in benchmark-based treatment.

On May 30, 2026, it was officially approved for market release by the US FDA.

Become China’s first internationally recognized innovative drug for intravenous anesthesia research and development

A molecular structural formula

behindIt is the result of thousands of days and nights of dedication by Chinese scientific researchers.

The Success of Ringapolone in Global Market

Not only a milestone in China’s medical innovation

It is also a ticket to the world“New business card”